- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07218302
Chatbot-Based Digital Therapy for Eating Disorders: A Research Study
Eating disorders affect approximately 10% of people during their lifetime, creating significant challenges for individuals and families. Despite how common these conditions are, less than 20% of those affected ever receive proper treatment. This research study aims to address this treatment gap by developing and testing a chatbot-based digital therapy program that provides accessible, evidence-based support for people struggling with eating disorders.
The study will use a cognitive behavioral therapy (CBT) approach, which is considered the gold standard treatment for eating disorders. Researchers will examine four key components of treatment: addressing excessive concern about weight and shape, reducing restrictive eating patterns, improving emotion regulation skills, and helping resist urges to binge eat. The study will involve 800 adults with binge or purge type eating disorders who are not currently in treatment.
Participants will be randomly assigned to receive different combinations of these treatment components through a digital chatbot program called Wysa. This program provides daily cognitive behavioral therapy-based exercises and support for eight weeks. Some participants will receive only one component, while others will receive various combinations of two, three, or all four components. A comparison group will receive referrals to seek other services.
The research team will assess participants at 1 month, 2 months, and 6 months after starting the program to measure changes in eating disorder symptoms, frequency of disordered eating behaviors, depression and anxiety symptoms, and how much the eating disorder affects daily functioning. Using advanced statistical methods, the researchers will identify which combination of treatment components works best while remaining efficient and practical for widespread use.
This research is particularly important because it addresses several critical barriers to eating disorder treatment. Traditional therapy can be expensive, difficult to access, and carries stigma that prevents many people from seeking help. Digital interventions like the chatbot being studied offer privacy, convenience, and affordability. They can reach people in rural areas, those with busy schedules, and individuals who might feel uncomfortable seeking in-person treatment.
For patients and caregivers, this research represents hope for more accessible treatment options. Eating disorders have among the highest mortality rates of any mental health condition, yet effective treatments remain out of reach for many. Digital interventions could potentially provide immediate support while someone is waiting for traditional therapy, serve as maintenance care after completing intensive treatment, or offer standalone support for those with mild to moderate symptoms.
The study has established partnerships with industry and nonprofit organizations to ensure that if the chatbot program proves effective, it can be quickly made available to the public. This focus on real-world implementation means that successful findings could rapidly translate into tangible help for those struggling with eating disorders.
Research in digital mental health interventions is increasingly important as technology becomes more integrated into daily life. Studies like this one help ensure that technological advancements in healthcare are grounded in solid scientific evidence and actually meet the needs of patients. The careful examination of which treatment components work best will help create more efficient and effective digital therapies, potentially benefiting not just those with eating disorders but people struggling with various mental health conditions.
For individuals and families affected by eating disorders, this research represents progress toward more accessible, affordable, and effective treatment options. As we await the results of this important study, it's encouraging to see innovative approaches being developed to address the significant treatment gap in eating disorder care.
Upcoming Clinical Trials
-
NCT07826949Not yet recruitingGlioma | Brain Neoplasm | Recurrent High-Grade Gliomas
-
NCT07826962Not yet recruiting
-
NCT07826975Not yet recruiting
-
NCT07826988Not yet recruitingSickle Cell Disease | Vaso-occlusive Crisis
-
NCT07827001RecruitingBrain Cancer | CNS Cancer | Nervous System Cancer | Brain Cancer Metastatic
-
NCT07827027Not yet recruiting
-
NCT07827040RecruitingAdults | Low Vision Digital Assistance | Visual Impairments
-
NCT07827053Not yet recruitingPancreatic Ductal Adenocarcinoma (PDAC)
-
NCT07827066Not yet recruitingSmoking Cessation | AI Agent | Early-Stage Cancer
-
NCT07827131Not yet recruiting